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1. Introduction 
Organic compounds obtained from radical coupling of phenylpropenoidic phenols have an 
important biological role. In fact, they constitute organic polymers such as lignin 
(Higuchi,1985) lignans (Ayers & Loike, 1990), suberin (Berdards et al. 1995) and algal cell 
walls (Ragan, 1984). To date, several hundreds of these lignans have been isolated. Whilst 
their biological role in plants is unclear and remains to be fully elucidated, they have been 
shown to display a substantial range of biological activity and have a long and fascinating 
medical history that emanates from their use as folk remedies to treat an assortment of 
conditions (Bett, 1951). They are typically dimers and their primary physiological role in 
plants is in plant defense (Beutner & Ferenczy, 1997). Some lignans have found application 
in medicine, such as podophyllotoxin in venereal wart treatment (Meresse et al, 2004), or its 
semisynthetic derivatives etoposide, and teniposide in cancer therapies (Ward, 1997).  
 
2. Aryltetraline lignans 
Aryltetralin lignans are lead substances for the semi-synthetic anticancer derivatives 
etoposide, teniposide and etopophos (Ionkova, 2007). The most prominent member of this 
group of natural products is podophyllotoxin (1) (Scheme 1). This compound, together with 
analogues (2-4) are aryltetralin lignan lactones isolated from the American Mayapple 
(Podophyllum peltatum) and related Indian species (Podophyllum emodi). Podophyllotoxin (1) 
has long been known to possess anti-mitotic activity with early clinical trials showing it to 
be highly efficacious but also quite toxic (Jardine, 1990), (Weiss et al., 1975) (Keller-Juslen et 
al., 1971). Four contiguous chiral centers contained within a stereochemically unstable trans-
fused tetrahydronaphthalene lactone skeleton (Ward, 1982) are present in this compound.   
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A number of modifications have been done on podophyllotoxin structure (Damayanthy & 
Lown, 1998), and some of the congeners exhibit a potent antitumor activity.  In fact, 
etoposide (5), teniposide (6), etopophos (7), GL-331 (8) (Kuo Hsiung-Lee, 2000) (Scheme 2) 
are potent chemotherapeutic agents for a variety of tumors. However, neither is optimal. For 
example, etoposide (5) and its analogues suffer from poor solubility and growing drug 
resistance. Consequently, further analogues continue to be described. GL-331 (8) is currently 
undergoing phase II clinical trials and has been shown to be more potent than etoposide as a 
topoisomerase II inhibitor and, more notably, has overcome multidrug resistance in cancer 
cells, including etoposide-resistant cancer cells (Xiao et al., 2004). 
In vivo studies have shown that metabolic deactivation of etoposide occurs through two key 
pathways, giving metabolites (9-10) (Cragg & Suffness, 1988) (Dow et a., 1982) (Creaven, 
1982) (Scheme 3).  
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Epimerisation of the trans lactone to the cis isomer (9) leads to a 100-fold loss in activity. 
Hydrolysis of the lactone with concomitant epimerisation leads to the hydroxy acid (10), 
which is 500-fold less active than etoposide. It can be deduced from these two observations 
that the stereochemistry surrounding the C ring of podophyllotoxin (1) is critical for the 
overall activity of the molecule. 
 
3. Antitumour Aryltetralines: Pharmacology 
Lignans, and especially cyclolignans, have been the objective of numerous studies focused 
on preparing better and safer anticancer drugs (Gordaliza et al., 2000). 
Etoposide (VP-16) and teniposide are currently in clinical use in the treatment of many 
cancers, particularly small cell lung carcinoma (SCLC), testicular cancer and malignant 
lymphoma.  
Etoposide gained FDA approval in 1983 and in 1987 a soft gelatin capsule formulation was 
approved as well, which allowed long-term and more tolerable drug administration.  
Clinical trials with etoposide began in 1971 and demonstrated its antineoplastic activity in 
AML (acute myeloid leukemia) (Kell, 2006), Hodgkin’s disease (Advani & Horning, 2006), 
non-Hodgkin’s lymphoma (Kluin-Nelemans et al., 2001), lung cancer, gastric cancer, breast 
cancer and ovarian and testicular cancer (Bookman et al. 2006). 
This semisynthetic derivative, along with teniposide, is usually administered in combination 
chemotherapy in the treatment of lung cancer (both small cell and non-small cell), testicular 
cancer and in acute leukaemias. Apart from ovarian and testicular cancer, etoposide has also 
been tried in other solid tumours including those of the brain and thymus and also in the 
treatment of Kaposi’s sarcoma associated with AIDS (Martindale, 2007). 
www.intechopen.com
Podophyllotoxin and antitumor synthetic aryltetralines. Toward a biomimetic preparation 307
O
O
O
H3CO
OCH3
OCH3
OH
O
H
H
podophyllotoxin 
(1) 1R, 2R, 3R, 4R
O
O
O
H3CO
OCH3
OCH3
OH
O
H
H
isopodophyllotoxin 
(2) 1S, 2R, 3R, 4R
O
O
O
H3CO
OCH3
OCH3
OH
O
H
H
epipodophyllotoxin
(3) 1R, 2R, 3R, 4S
O
O
O
H3CO
OCH3
OCH3
OH
O
H
H
epiisopodophyllotoxin
(4) 1S, 2R, 3R, 4S
Scheme 1
  
etopophos
(7) 1R, 2R, 3R, 4S
O
O
O
H3CO
OCH3
OCH3
O
O
H
H
P
O
HO OH
etoposide
(5) 1R, 2R, 3R, 4S
O
O
O
H3CO
OCH3
OCH3
O
O
H
H
HO
HO OOH
CH3
O
O
O
H3CO
OCH3
OCH3
O
O
H
H
HO
HO OOH
S
teniposide
(6) 1R, 2R, 3R, 4S
GL-331
(8) 1R, 2R, 3R, 4R
O
O
O
H3CO
OCH3
OCH3
NH
O
H
H
O2N
Scheme 2
  
A number of modifications have been done on podophyllotoxin structure (Damayanthy & 
Lown, 1998), and some of the congeners exhibit a potent antitumor activity.  In fact, 
etoposide (5), teniposide (6), etopophos (7), GL-331 (8) (Kuo Hsiung-Lee, 2000) (Scheme 2) 
are potent chemotherapeutic agents for a variety of tumors. However, neither is optimal. For 
example, etoposide (5) and its analogues suffer from poor solubility and growing drug 
resistance. Consequently, further analogues continue to be described. GL-331 (8) is currently 
undergoing phase II clinical trials and has been shown to be more potent than etoposide as a 
topoisomerase II inhibitor and, more notably, has overcome multidrug resistance in cancer 
cells, including etoposide-resistant cancer cells (Xiao et al., 2004). 
In vivo studies have shown that metabolic deactivation of etoposide occurs through two key 
pathways, giving metabolites (9-10) (Cragg & Suffness, 1988) (Dow et a., 1982) (Creaven, 
1982) (Scheme 3).  
O
O
O
H3CO
OH
OCH3
O
OH
HO
HO OOH
CH3
H
O
O
H3CO
OH
OCH3
O
H
HO
HO OOH
CH3
COOH
H
CH2OH
(9) (10)
Scheme 3
  
Epimerisation of the trans lactone to the cis isomer (9) leads to a 100-fold loss in activity. 
Hydrolysis of the lactone with concomitant epimerisation leads to the hydroxy acid (10), 
which is 500-fold less active than etoposide. It can be deduced from these two observations 
that the stereochemistry surrounding the C ring of podophyllotoxin (1) is critical for the 
overall activity of the molecule. 
 
3. Antitumour Aryltetralines: Pharmacology 
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treatment of Kaposi’s sarcoma associated with AIDS (Martindale, 2007). 
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In particular, cisplatin or carboplatin with etoposide remains the current standard 
chemotherapy regimen for small cell lung carcinoma, which accounts for about 10-20% of all 
lung cancers (Yee et al., 2008) and is the most aggressive form of lung cancer, with an overall 
5-year survival less than 5%. 
Germ cell tumours are the most common solid malignancies to affect young adult men and 
their incidence is increasing worldwide (Hussain et al., 2008). Advanced testicular cancer is 
successfully treated with etoposide, in combination chemotherapy with cisplatin and 
bleomycin (Feldman et al., 2008).  
The dose-limiting toxicity of etoposide is myelosuppression, mainly seen as leucopenia, but 
also thrombocytopenia and sometimes anaemia. The nadir of the granulocyte count usually 
occurs 7 to 14 days after a dose, with recovery by about 21 days. Nausea and vomiting are 
common and gastrointestinal toxicity may be more common after oral dosage. Reversible 
alopecia occurs in about two-thirds of all patients. Hypersensitivity or anaphylactoid 
reactions can occur, characterized by flushing, chills, fever, tachycardia, bronchospasm, 
dyspnoea and hypotension. Peripheral or central neuropathies have been rarely observed. 
Tumor lysis syndrome has been reported after the use of etoposide with other 
chemotherapeutic drugs. Disturbances of liver function have been reported, mainly at high 
doses, and there have been occasional reports of cardiotoxicity. 
Pharmacokinetic parameters determined from studies have shown that the area under the 
concentration versus time curve (AUC) and peak plasma concentrations achieved following 
i.v. etoposide administration are linearly related to dose (Hande et al., 1984). Etoposide’s 
steady-state volume of distribution ranges from 5 to 171/m2. Etoposide is highly bound to 
plasma proteins with an average free plasma fraction of 6%. Total etoposide clearance is 
modestly decreased in patients with renal failure, but not in patients with hepatic 
obstruction. The etoposide plasma binding ratio (the amount of bound drug/the amount of 
free drug) is directly related to the serum albumin concentration. Cancer patients, in 
particular those with hepatic involvement, often have reduced serum albumin 
concentrations. Since free etoposide is biologically active, conditions which decrease protein 
binding increase the pharmacological effect of a given dose. 
The bioavailability of oral etoposide, ranges from 40 to 75%, changes with the drug dose and 
shows a considerable interindividual variability has been reported. 
As etoposide is poorly soluble in water, the intravenous administration of large doses of the 
drug may require the administration of significant fluid volumes, and this fluid load can 
cause heart failure in some patients (Hande, 1998). Hypersensitivity reactions and 
hypotension may also occur with rapid administration of etoposide, perhaps due to the 
vehicles needed as solubilisers. To overcome solubility problems, etoposide phosphate 
(Etopophos®, Bristol-Myers Squibb Co), an etoposide prodrug for intravenous use, was 
produced and was approved by the FDA in 1996. 
Etoposide phosphate can be administered more rapidly and seems to be associated to a 
reduced number of hypersensitivity reactions (Collier et al., 2008). This compound is soluble 
in water at concentrations up to 20 mg/ml. Several studies have shown that etoposide 
phosphate is rapidly and completely converted to etoposide by the action of alkaline 
phosphatases in blood,  and it can be administered over short (5-30 min) time periods, is 
pharmacokinetically equivalent to etoposide and has identical toxicity. Conversion to 
etoposide is rapid and not saturated even at high drug doses (1.6 g/m2) used in marrow 
transplantation regimens. 
In patients with high risk or relapsed lymphoma, high-dose etoposide phosphate proved to 
be bioequivalent to high-dose etoposide (Reif et al., 2001). The compound showed an 
acceptable toxicity and is successfully used with carboplatin in elderly patients with small-
cell lung cancer (Quoix et al., 2001). 
Teniposide was approved for clinical use in the US in 1993 and it is used primarily in the 
treatment of leukemias and lymphomas, mainly in childhood. Its toxicity is identical to 
those of etoposide. It can induce myelosuppression, hair loss, nausea, mild vomiting and 
mucositis, along with occasional hypersensitivity reactions. 
 
4. Antitumour Aryltetralines: Mechanism of action  
The mechanism by which the aryltetralin lignan podophyllotoxin (1) blocks cell division is 
related to its inhibition of microtubule assembly into the mitotic apparatus. However, 
etoposide and teniposide were shown not to be inhibitors of microtubule assembly. This 
suggested that their antitumor properties were due to another mechanism of action: their 
interaction with DNA. In fact, they induce a block in late phase S or early G2 by interacting 
with the enzyme topoisomerase II (Botta et al., 2001). 
DNA topoisomerases are nuclear enzymes which make transient DNA strand breaks, 
allowing the cell to manipulate the topology of its DNA. These enzymes are essential for 
DNA replication, transcription, chromosomal segregation and DNA recombination. They 
act by cleaving one or both DNA strands, allowing the passage of an unbroken strand or 
DNA duplex through the breakage site prior to resealing the break. As a result of their 
double-stranded DNA passage reaction, type II topoisomerases are able to regulate over- 
and under-winding of the double helix and resolve nucleic acid knots and tangles. 
It was not until 1979 that the name “DNA topoisomerases” was introduced. Extensive 
biochemical analysis of this group of enzymes was undertaken at the same time etoposide 
was  brought to the clinic.  
Etoposide was the first agent recognized as a topoisomerase II inhibiting anticancer drug: in 
1984, several laboratories demonstrated that mammalian topoisomerase II was the target for 
etoposide action.  
This compound and other topoisomerase II inhibitors do not kill cells by blocking 
topoisomerase catalytic function. They poison these enzymes by increasing the steady-state 
concentration of their covalent DNA cleavage complexes. This action converts 
topoisomerases into physiological toxins that introduce high levels of transient protein-
associated breaks in the genome of treated cells. 
The potential lethality of these drug-induced cleavage complexes rises dramatically when 
replication machinery or helicases attempt to traverse the covalently bound topoisomerase 
roadblock in the DNA. This disrupts the cleavage complex and converts transient single- or 
double-strand breaks into permanent double-stranded fractures which are no longer held 
together by proteinaceous bridges. These breaks become targets for recombinations, sister 
chromatid exchange, the generation of large insertions and deletions and the production of 
chromosomal aberrations and translocation. When these permanent DNA breaks are present 
at sufficient concentration, they trigger a series of events that ultimately culminate in cell 
death by apoptosis. 
As most topoisomerase II inhibiting agents are substrates for P-glycoprotein or other 
multidrug resistance associated proteins, the development of newer and better 
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podophyllotoxin-based strategies for the treatment of malignant disease may be 
forthcoming (Liu et al., 2007). 
Other podophyllotoxin derivatives which retain or even improve the cytotoxic activity have 
been studied, but these are weak inhibitors of topoisomerase  II in vitro; the data revealed 
that such analogs exhibit a different, as yet unknown, mechanism of action. The main 
deficiency of these compounds is their cytotoxicity for normal cells and hence the side 
effects derived from their lack of selectivity against tumoral cells. With this regard it is 
necessary to investigate and prepare new more potent and less toxic analogs, with better 
therapeutic indices. 
 
5. Synthetic Routes  
Since its first isolation in 1953 (Hartwell et al., 1953), podophyllotoxin (1) and its isomers 
have been the subject of numerous synthetic endeavours (Pelter et al., 1998), (Ward 1990, 
1992, 2004).  
The particular challenge for podophyllotoxin (1) is in establishing the 1,2-cis stereochemistry 
together with a trans lactone ring fusion (Sellars & Steel, 2007). Because of the different 
stability of the stereoisomers, on mild base treatment, podophyllotoxin undergoes rapid 
epimerisation to afford a 97.5:2.5 mixture of picropodophyllin and podophyllotoxin (Gensler 
& Gatsonis, 1966). 
PM3 calculations show in fact that podophyllotoxin and GL-331 are 1.1 kcal/mol more 
stable than isopodophyllotoxin and iso-GL-331 respectively (Rindone, 2009).  
 
The most common approach for the aryltetralin lactone skeleton is the electrophilic aromatic 
substitution forming the C1–C6 bond and simultaneously establishing the stereochemistry 
at C1. A three-component coupling strategy for aryltetralin lignan lactone synthesis is 
shown in Scheme 4. 
a) C-Ring Formation by Aryl Substitution 
This involve an acyl anion equivalent (11), a butenolide Michael acceptor (12) and an 
aldehyde (13). Intermediate (14) is formed and is cyclised to compound (15), having a  1,2-
trans,2,3-trans stereochemistry (Pelter et al, 1990), (Gonzales et a., 1978) (Van Speybroek et al. 
1991). 
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The other principal strategy for the construction of the cyclic system is the Diels–Alder 
reaction. The oxabicyclo adduct (19) derived from the the isobenzofuran (17) and 
dimethylmaleate (18) gives an intermediate (20)  which is further transformed into 
podophyllotoxin (1) (Rodrigo, 1980), (Rajapaksa & Rodrigo, 1981) (Forsey et al., 1989), (Jones 
et al., 1987), (Kuroda et al., 1996) (Scheme 5).  
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The other principal strategy for the construction of the cyclic system is the Diels–Alder 
reaction. The oxabicyclo adduct (19) derived from the the isobenzofuran (17) and 
dimethylmaleate (18) gives an intermediate (20)  which is further transformed into 
podophyllotoxin (1) (Rodrigo, 1980), (Rajapaksa & Rodrigo, 1981) (Forsey et al., 1989), (Jones 
et al., 1987), (Kuroda et al., 1996) (Scheme 5).  
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The application of a Michael-induced ring-closure using a chiral intermediate gives the 
formation of the  1,2-trans stereochemistry. One example is the reaction of a tungsten-
carbene (22) with the chiral methylendioxyalkylstyrene epoxide (21) to form a reaction 
product (23) having a 1,2-trans,2,3-cis stereochemistry (Kende et al., 1981), (Capriati et al., 
2005) (Scheme 6). 
c) C-Ring Construction via Michael Induced Ring Closure 
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Alternatively, an intramolecular Heck reaction starting from the iododerivative (24) forms 
compound (25), subsequently transformed into podophyllotoxin (1) (Kennedy-Smith et al., 
2004) (Scheme 7). 
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Some other synthetic pathways have been performed introducing in the molecule a chiral 
auxiliary intended to drive the formation of the stereogenic centers in reactions performed 
using the methodologies exposed in the preceding paragraphs. 
d) The use of chiral auxiliaries 
 
 
 
d1): The enantioselective dearomatisation of a naphthalene derivative (26) resulted in the 
generation of the 1,2-trans stereochemistry in (27) which may be converted into (28), having 
1,2-trans,2,3-cis stereochemistry (Scheme 8) (Andrews et al, 1988).  
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d2): The condensation of a chiral benzyl-γ-butyrolactone (30) with piperonal (29) gives 
compound (31). Subsequent alkylation and cyclization gives 
demethyldeoxyisopodophyllotoxin (32), having a 1,2-trans,2-3 trans stereochemistry 
(Engelhardt et al. 2003) (Scheme 9). 
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d3): The coniugate addition of the menthyl derivative (34) with the benzyl cyanide (33) and 
a substituted benzaldehyde (35) gave intermediate (36). Removal of the menthyl fragment 
resulted in the formation intermediate (36) and then of  aryltetraline (37) with a 1,2-trans, 
2,3-cis stereochemistry (Ward et al., 1998)  (Scheme 10). 
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d4): Menthyloxyfuranone (39) and pyrones (38) gave the endo adduct (40) which was 
transformed into podophyllotoxin (1) with 1,2-cis-2,3-trans stereochemistry by acid-
promoted elimination of the lactone bridge in intermediate (40) (Bush & Jones, 1996) 
(Scheme 11). 
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d5): A Diels-Alder cycloaddition between the fumarate of methyl (S)-mandelate (42) and α-
hydroxy-α-aryl-o-quinodimethane (41) produces an endo cycloadduct (43) which may be 
converted into optically pure (-)-deoxypodophyllotoxin (44) having 1,2-cis,2,3-trans 
stereochemistry (Bogucky & Charlton, 1995) (Scheme 12). 
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d6): A Diels-Alder cycloaddition between the fumarate of methyl ( S )-mandelate (46) and α-
hydroxy-α'-aryl-o-quinodimethane (45) gives optically pure (-)-α-dimethylretrodendrin (47) 
having a 1,2-trans-2,3-trans stereochemistry, and three of its diastereomers (Scheme 13) 
(Charlton et al., 1990), (Charlton & Koh, 1992), (Maddaford & Charlton, 1993). 
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6. The biomimetic strategy 
One alternative is the biomimetic pathway, using the oxidative phenol coupling reaction 
which is the strategy the cell uses for the biosynthesis of lignans. 
Recently Lewis has proposed a new biosynthetic pathway to enantiopure lignans. A protein 
isolated from Forsythia species is suggested to be responsible for the formation of 
enantiomeric pure pinoresinol from coniferyl alcohol (Lewis & Davin, 1999). In this case, the 
protein acts as a chiral inducer. The role of the directing protein is supposed to be at the 
level of 8-8 coupling of phenols.  
The in vitro bimolecular phenoxy radical coupling reaction is not under a strictly regio- and 
stereospecific control. This is due to the fact that phenoxy radicals are very persistent and 
the dimerization reaction is slow. Hence the stereogenic carbons formed in the oxidative 
phenol coupling reaction in vitro are racemic. Sarkanen has studied the radical phenol 
coupling since 1973 and he has demonstrated that the 8-8 coupling of phenols such as (E)-
isoeugenol is remarkably stereospecific and produces exclusively threo compounds, whereas 
(Z)-isoeugenol gives threo- and erythro-coupling products in equal amounts. He has 
proposed that the differences in the probabilities of coupling modes in the oxidations of (E) 
and (Z)-isoeugenol must be considered to be due to the characteristics of these intermediate 
complexes rather than to the differences in spin densities (Sarkanen & Wallis, 1993).  
The enzymatic oxidative coupling of ferulic acid derivatives was observed by us to result in 
the diastereoselective synthesis of benzo[b]phenylcoumarans (Bolzacchini et al., 1998). 
Stereocontrol in this reaction to enantioselectively give benzo[b]phenylcoumarans has been 
recently shown by us to be possible (Rummalko et al., 1999) using a chiral inducer and the 
horseradish peroxidase (HRP)-catalyzed oxidative coupling in presence of hydrogen 
peroxide as the oxidant. The chiral inducers were aminoacid ethyl esters, camphorsultam 
and aryloxazolidinones (Bruschi et al., 2006). 
 
6.1 Metal-mediated oxidative phenol coupling 
a): The oxidative phenol coupling of compound (48) with silver oxide gave, after acetylation, 
a mixture of the aryltetraline (49), with a 1,2-trans stereochemistry and a 3,4 double bond,  
the benzo[kl]xanthene (50) and the benzodioxane (51) (Maeda et al., 1994) (Scheme 14).  
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b: ) 2-hydroxycinnamates (52) underwent oxidative phenol coupling with silver oxide to 
give, after acetylation, compound (53) (Maeda et al., 1995) having 1,2-trans stereochemistry 
and a 3,4-double bond (Scheme 15). 
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c: ) With MnO2, the oxidative phenol coupling using compound (54) as the starting material 
gave the aryltetralin (55) having a 1,2-trans stereochemistry and a 3,4-double bond uand the 
benzo[kl]xanthene (56) (Scheme 16) (Daquino et al., 2009). 
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d: ) The triallylderivative of (S)-rosmarinic acid (57) was submitted to FeCl3-assisted 
oxidative phenol coupling forming the diastereoisomers (58-59) of rabdosiin, having a 1,2-
trans stereochemistry and 3,4-double bond (Bogucki & Charlton, 1997) (Scheme 17). 
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e: ) (R)-mandelyl sinapate (60) was diastereoselectively transformed by FeCl3-assisted 
oxidative phenol coupling into trans-thomasidioate diester (61-62), having a 1,2-trans 
stereochemistry and a 3-4 double bond (Bogucki & Charlton, 1997) (Scheme 18). 
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6.2 Enzyme-catalyzed oxidative phenol coupling 
a: ) Amide (63), submitted to oxidative phenol coupling with hydrogen peroxide in the 
presence of horseradish peroxidase gave a mixture of the levorotatory isomer of the 
aryltetraline cannabisin (64), having a 1,2-cis stereochemistry and a 3,4 double bond, and the 
phenylcoumaran grossamide, (65) (Scheme 19) (Lajide et al., 1995). 
 
www.intechopen.com
Podophyllotoxin and antitumor synthetic aryltetralines. Toward a biomimetic preparation 319
c: ) With MnO2, the oxidative phenol coupling using compound (54) as the starting material 
gave the aryltetralin (55) having a 1,2-trans stereochemistry and a 3,4-double bond uand the 
benzo[kl]xanthene (56) (Scheme 16) (Daquino et al., 2009). 
 
O
O
HO
HO
MnO2
O
O
O
O
O
OH
OH
HO
O
O
O
O
OH
OH
HO
Scheme 16
(54)
(55)
(56)
HO
  
d: ) The triallylderivative of (S)-rosmarinic acid (57) was submitted to FeCl3-assisted 
oxidative phenol coupling forming the diastereoisomers (58-59) of rabdosiin, having a 1,2-
trans stereochemistry and 3,4-double bond (Bogucki & Charlton, 1997) (Scheme 17). 
 
HO
HO
O
O O
O
OO FeCl3
HO
HO
O
O
O
OH
HO
COOH
OH
OH
O
COOH
HO
HO
HO
HO
O
O
O
OH
HO
COOH
OH
OH
O
COOH
HO
HO
Scheme 17
(57)
(58)
(59)
 
e: ) (R)-mandelyl sinapate (60) was diastereoselectively transformed by FeCl3-assisted 
oxidative phenol coupling into trans-thomasidioate diester (61-62), having a 1,2-trans 
stereochemistry and a 3-4 double bond (Bogucki & Charlton, 1997) (Scheme 18). 
 
H3CO
HO
H3CO
OH
OCH3
H3CO
HO
OCH3
O
O COOCH3
FeCl3
OCH3 O
O
O
O COOCH3
COOCH3
H3CO
HO
H3CO
OH
OCH3
OCH3 O
O
O
O COOCH3
COOCH3
Scheme 18
(60)
(61)
(62)   
6.2 Enzyme-catalyzed oxidative phenol coupling 
a: ) Amide (63), submitted to oxidative phenol coupling with hydrogen peroxide in the 
presence of horseradish peroxidase gave a mixture of the levorotatory isomer of the 
aryltetraline cannabisin (64), having a 1,2-cis stereochemistry and a 3,4 double bond, and the 
phenylcoumaran grossamide, (65) (Scheme 19) (Lajide et al., 1995). 
 
www.intechopen.com
Biomimetics, Learning from Nature320
HO
OH
OMe
H
N
HN
O
O
OH
OH
MeO
MeO
HO OMe
O
N
H
+
O
HN
O
OH
OH
OHOMe
N
H
O
HO
OMe
Scheme 19
(63)
(64)
(65)
OH
  
b:) The enantioselective oxidative phenol coupling of sinapic acid derivatives (66) (Scheme  
18) having an amide bond with (S)-phenylalanine ethyl ester, (S)-methylbenzylamine, (S)-2-
phenyloxazolidinone as chiral auxiliaries was performed using hydrogen peroxide as the 
oxidant and horseradish peroxidase as the catalyst (Zoia et al., 2008). 
The proposed reaction pathway involves two steps; the first step is the 8-8 oxidative 
coupling of two phenoxy radicals (67) to give the bisquinomethide (68) , and the second step 
is the ring closure of (68) to give the final product. For this mechanism the absolute 
configuration of thomasidioic acid amide (69) should be determined by the absolute 
configuration of the two stereogenic centers of the bisquinomethide (68)  formed in the 8-8 
oxidative coupling, and by its  trans or cis ring closure (Scheme 20). 
The computed profile along the reaction pathway for the 8-8 coupling at the re-re, si-si, and 
re-si faces shows that the energy barrier calculated for the si-si coupling is higher by more 
than 4 kcal·mol-1 than that calculated for the re-re and re-si coupling. This result suggests 
that the formation of the R,R (from re-re coupling), and R,S/S,R (from re-si coupling) 
bisquinomethide (68)  is preferred with respect to the formation of the S,S (from si-si 
coupling) bisquinomethide (68). 
The cyclization step determines the observed diasteroselection to the trans isomer. The 
diasteroselection should be controlled by the relative orientation of the two quinomethide 
rings which should feature a preferred conformation in order to give the “correct” ring 
closure, as well as to the energy of the transition state along the reaction path to give the 
final product. 
A conformational analysis was  performed in order to predict the enantioselectivity in the 
formation of trans-thomasidioic acid amide (69) from quinomethide (68) having a (S)-2-
phenyloxazolidinone chiral auxiliary group. 
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Our computational investigation of the 8-8 oxidative coupling of quinomethide radical (67) 
shows that the R,R, S,S and R,S, S,S isomers of bisquinomethide (68) should be formed in 
larger amounts with respect to the S,S, S,S isomer. The former, after aromatization preserves 
only one R centre that gives ring closure to the trans 1S,2R absolute configuration, while the 
latter after aromatization can preserve both an R or S centre, giving ring closure to both the 
trans 1S,2R, and 1R,2S absolute configurations. Hence, the configuration of thomasidioic 
acid amide (69) from this  enantioselective synthesis is predicted to be 1S,2R. 
 
7. References 
Advani R., Horning S.J., J. Natl. Compr. Canc. Netw., 2006, 4 (3),  241-7. 
Andrews, R. C., Teague, S. J., Meyers, A. I., J. Am. Chem. Soc., 1988,  110, 7854-7858. 
Ayers, D., C.; Loike, J. D.; Lignans. Chemical biological and clinical properties; Cambridge 
University Press, Cambridge 1990, pp 278-373.  
Bernards, M. A.; Lopez, M. L.; Zajicek, J.; Lewis, N. G.; J. Biol. Chem., 1995, 270, 7382-7387. 
Bett, W. R., Practitioner 1951, 166, 77. 
Beutner, K. R.; Ferenczy, A. Am. J. Med. 1997, 102, 28-37. 
Bolzacchini, E.; Brunow, G.; Meinardi, S.; Orlandi, M.; Rindone, B.; Rummakko, P.; Setälä, 
H.; Tetrahedron Lett., 1998, 39, 3291-3294. 
Bogucki; D. E., Charlton, J. L.,  J. Org. Chem.,  1995,  60,  588-593.   
Bogucki, D. E.,  Charlton, J. L., Can. J. Chem., 1997, 75, 1783-1794. 
Bookman, M. A., McMeekin, D. S., Fracasso, P. M., Gynecologic Oncology , 2006,  103(2),  473-
478.    
Botta B., Delle Monache G., Misiti D., Vitali A., Zappia G., Current medicinal Chemistry, 2001,  
8 (11), 1363-81, 2001. 
Bruschi. M.; Orlandi. M.; Rindone, B.; Rummakko, P.; Zoia, L.; J. Phys. Org. Chem., 2006, 19, 
592-596. 
Bush, E. J., Jones, D. W., J. Chem. Soc. Perkin Trans. 1, 1996, 151–155. 
Capriati, V. Florio, S., Luisi, R., Perna, F. M., Salomone, A., Gasparrini, F., Org. Lett. 2005, 7, 
4895–4898. 
Charlton, J. L., Plourde, G. L.,  Koh, K., Secco, S., Can. J. Chem., 1990, 68, 2022–2027 
Charlton, J. L., Koh, K., J. Org. Chem. 1992, 57, 1514–1516 
Collier K., Schink C., Young A.M., How K., Seckl M., Savage P., J. Oncol. Pharm. Pract. 2008, 
14 (1), 51-5. 
Cragg, G., Suffness, M.,  Pharmacol. Ther. 1988, 37, 425–461 
Creaven, P. J., Cancer Chemother. Pharmacol. 1982, 7, 133–140. 
Damayanthi Y., Lown J.W., Curr Med Chem. 1998, Jun 5 (3),  205-52. 
Daquino, C., Spatafora, C., Tringali, C., unpublished results. 
Dow, L. W.,  Sinkule, J. A.,  Look, A. T.,  Horvath, A. Evans, W. E., Cancer Res. 1983, 43, 
5699–5706 
Engelhardt, U., Sarkar, A., Linker, T., Angew. Chem. Int. Ed.2003, 42, 2487–2489. 
Feldman D.R., Bosl G.J., Scheinfeld J., Motzer R.J., JAMA, 2008,  299 (6): 672-84. 
Forsey, S. P., Rajapaksa, D., Taylor, N. J.,  Rodrigo, R., J. Org.Chem. 1989, 54, 4280–4290 
Gensler, W. J., Gatsonis, C. D., J. Org. Chem. 1966, 31, 3224–3227. 
Gonzalez, A. G., Perez, J. P., Trujillo, J. M., Tetrahedron 1978, 34, 1011–1013 
Gordaliza M., Castro M.A., del Corral J.M., Feliciano A.S., Curr Pharm Des., 2000, 6 (18), 
1811-39. 
Hande K.R., Wedlund P.J., Noone R.N. et al., Cancer Res, 1984, 44: 379-82. 
Hande K.R, Eur. J. Cancer, 1998, 34 (10), 1514-21. 
Hartwell, J. L., Johnson, J. M., Fitzgerald, D. B., Belkin, M., J.Am. Chem. Soc. 1953, 75, 235–
236. 
Higuchi, T.; Biosynthesis of Lignin, In Biosynthesis and Biodegradation of  Wood Component 
Higuchi, T. Ed.; Academic Press Inc., New York 1985, pp 141-148. 
Hussain S.A., Ma Y.T., Cullen M.H., Expert Rev. Anticancer Ther, 2008, 8 (5): 771-84. 
Kell J., Rev. Recent Clin. Trials 2006, 1 (2),  103-11. 
Keller-Juslen, C., Kuhn, M., Stahelin, H., von Wartburg, A., J.Med. Chem. 1971, 14, 936–940.   
Kende, A. S., King, M. L., Curran, D. P.,  J. Org. Chem. 1981, 46, 2826–2828 
Kennedy-Smith, J. J., Young, L. A., Toste, F. D. Org. Lett. 2004, 6, 1325–1327. 
Kluin-Nelemans H.C., Zagonel V., Anastasopolou A., Bron D., Roodendaal K.J., Noordijk 
E.M., Musson H., Teodorovic I., Maes B., Carbone A., Carde P., Thomas J., J. Natl. 
Cancer Inst., 2001, 93 (1),  22-30. 
Kuo Hsiung-Lee, Antitumor Agents 188, 2000. 
Kuroda, T., Takahashi, M., Kondo, K.,  Iwasaki, T., J. Org. Chem.1996, 61, 9560–9563. 
Ionkova, I. Pharmacognosy Reviews  2007,  1(1),  57-68. 
Jardine, I., Anticancer Agents based on Natural Products, Academic  Press, NewYork, 1980. 
Jones, D. W., Thompson, A. M., J. Chem. Soc. Chem. Commun.1987, 1797–1798 
Lajide, L., Escoubas, P., Mizutani, J. Phytochemistry, 1995, 40, 1105-1112. 
Lewis, N, G.; Davin, L. B. Lignans: biosynthesis and function. In Comprehensive Natural Products 
Chemistry, vol 1.; Barton, Sir D. H. R.; Nakanishi, K.; Meth-Cohn, O., (Eds.); Elsevier: 
Oxford, UK, 1999; pp. 639-712. 
Liu Y.Q., Yang L.M., Tian X., Curr. Bioactive Compounds, 2007,  3 (1),  37-66. 
Maddaford, S. P.; Charlton, J. L;  J. Org. Chem., 1993,  58,  4132-4138.   
Maeda, S., Masuda, H., Tokoroyama, T., Chem. Pharm. Bull., 1994, 42, 2506-2513. 
Maeda, S., Masuda, H., Tokoroyama, T., Chem. Pharm. Bull., 1995, 43, 35-40. 
Martindale, R. G., The Complete Drug Reference, 35th edition, 2007. 
Meresse, P.; Dechaux, E.; Monneret, C.; Bertounesque, E. Curr. Med. Chem. 2004, 11, 2443-
2466. 
Pelter, A., Ward, R. S., Pritchard, M. C., Kay, I. T.  J. Chem. Soc.Perkin Trans. 1, 1988, 1603–
1613 
Pelter, A., Ward, R. S., Jones, D. M., Maddocks, P., Tetrahedron:Asymmetry 1990, 1, 855–856 
Quoix E., Breton J.L., Daniel C., Jacoulet P., Debieuvre D., Paillot N., Kessler R., Moreau L., 
Liu Y.Q., Yang L.M., Tian X., Coetmeur D., Lemarié E., Milleron B., Ann. Oncol., 
2001, 12 (7),  957-62.. 
Ragan, M. A.;  Phytochemistry, 1984, 23, 2029-2032.  
Rajapaksa, D., Rodrigo, R., J. Am. Chem. Soc. 1981, 103, 6208–6209 
Reif S., Kingreen D., Kloft C., Grimm J., Siegert W., Schunack W., Jaehende U., Cancer 
Chermother. Pharmacol, 2001, 48 (2),  134-40. 
Rindone, B. Unpublished results 
Rodrigo, R., J. Org. Chem. 1980, 45, 4538–4540 
Rummalko, P.; Brunow, G.; Orlandi, M.; Rindone, B.;  Synlett, 1999,  333-335. 
Sarkanen, K. V.; Wallis, A. F. A.  J. Chem. Soc. Perkin I 1973, 1869-1878.    
www.intechopen.com
Podophyllotoxin and antitumor synthetic aryltetralines. Toward a biomimetic preparation 323
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